{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Berger S"],"funding":["NIAID NIH HHS","NCI NIH HHS","NIGMS NIH HHS"],"pagination":["4305-4317.e18"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11316638"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["187(16)"],"pubmed_abstract":["Interleukin (IL)-23 and IL-17 are well-validated therapeutic targets in autoinflammatory diseases. Antibodies targeting IL-23 and IL-17 have shown clinical efficacy but are limited by high costs, safety risks, lack of sustained efficacy, and poor patient convenience as they require parenteral administration. Here, we present designed miniproteins inhibiting IL-23R and IL-17 with antibody-like, low picomolar affinities at a fraction of the molecular size. The minibinders potently block cell signaling in vitro and are extremely stable, enabling oral administration and low-cost manufacturing. The orally administered IL-23R minibinder shows efficacy better than a clinical anti-IL-23 antibody in mouse colitis and has a favorable pharmacokinetics (PK) and biodistribution profile in rats. This wo"],"journal":["Cell"],"pubmed_title":["Preclinical proof of principle for orally delivered Th17 antagonist miniproteins."],"pmcid":["PMC11316638"],"funding_grant_id":["P30 CA016087","P30 GM124165","T32 AI007290"],"pubmed_authors":["Pultz IS","Gropp R","Glassman C","Baker D","Naik S","Sniezek C","Murphy M","Guenin-Mace L","Kang A","Ahlrichs M","Stewart L","Blackstone A","Rosenblum D","Carter L","Siebeck M","Bera AK","Yang H","Garcia KC","Beigel F","Ravichandran R","Seeger F","Yu TY","Spangler JB","Arguinchona L","Berger S","Aydin M"],"additional_accession":[]},"is_claimable":false,"name":"Preclinical proof of principle for orally delivered Th17 antagonist miniproteins.","description":"Interleukin (IL)-23 and IL-17 are well-validated therapeutic targets in autoinflammatory diseases. Antibodies targeting IL-23 and IL-17 have shown clinical efficacy but are limited by high costs, safety risks, lack of sustained efficacy, and poor patient convenience as they require parenteral administration. Here, we present designed miniproteins inhibiting IL-23R and IL-17 with antibody-like, low picomolar affinities at a fraction of the molecular size. The minibinders potently block cell signaling in vitro and are extremely stable, enabling oral administration and low-cost manufacturing. The orally administered IL-23R minibinder shows efficacy better than a clinical anti-IL-23 antibody in mouse colitis and has a favorable pharmacokinetics (PK) and biodistribution profile in rats. This wo","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-04-12T19:30:38.615Z","creation":"2026-04-07T13:21:10.022Z"},"accession":"S-EPMC11316638","cross_references":{"pubmed":["38936360"],"doi":["10.1016/j.cell.2024.05.052"]}}